TOP > 外国特許検索 > ANTIGEN-AND-DRUG VEHICLE COMPRISING SYNTHETIC PEPTIDE, AND MUCOSAL VACCINE USING THE SAME

ANTIGEN-AND-DRUG VEHICLE COMPRISING SYNTHETIC PEPTIDE, AND MUCOSAL VACCINE USING THE SAME 実績あり

外国特許コード F110002753
整理番号 S2008-0401-C0
掲載日 2011年4月13日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2009JP056508
国際公開番号 WO 2009123119
国際出願日 平成21年3月30日(2009.3.30)
国際公開日 平成21年10月8日(2009.10.8)
優先権データ
  • 特願2008-096244 (2008.4.2) JP
発明の名称 (英語) ANTIGEN-AND-DRUG VEHICLE COMPRISING SYNTHETIC PEPTIDE, AND MUCOSAL VACCINE USING THE SAME 実績あり
発明の概要(英語) Disclosed are: an antigen-and-drug (AD) vehicle utilizing a novel synthetic peptide; and a mucosal vaccine. Specifically disclosed are: an antigen-and-drug (AD) vehicle comprising a complex of a lipid and a synthetic peptide which can induce the production of a secreted IgA antibody and comprises the amino acid sequence PVHLKRLm [wherein m represents a number of 11 to 15 or 16-20; e.g., the peptide depicted in SEQ ID NO:1] or KnLm [wherein n represents a number of 4 to 8 and m represents a number of 11 to 20; e.g., the peptide depicted in SEQ ID NO:2 or SEQ ID NO:3]; and a mucosal vaccine produced by allowing such an amount of an antigen that a mucosal immunity IgA can be induced to coexist with the AD vehicle, by contacting the above-mentioned amount of an antigen with the AD vehicle, by capturing above-mentioned amount of an antigen by the AD vehicle, or by adsorbing the above-mentioned amount of an antigen on the AD vehicle.
従来技術、競合技術の概要(英語) BACKGROUND ART
Patent Document 1 and 2 is, like the conventional inactivated vaccines or the disadvantages of the toxoid, such as immune adjuvants and mucosal vaccine development of current has been described in detail.
These Patent Documents 1, as described in 2, such as conventional intramuscular subcutaneously inoculated into from a vaccine, is the root of a natural infection of the virus to induce the production of the antibody IgA mucosa of switching to the mucosal vaccine need, wider and deeper recognized. In particular, as the next generation vaccine 21 st century, the production of antibodies IgA, inducing an immune response or mucosal local immune, so-called mucosal vaccine development and practical use is possible for the deficiencies of all over the world, has not been achieved yet.
The present inventors to solve this problem, the surfactant and the surfactant and/or pulmonary lung C B, lipid antigen in a complex with a drug (AD) and the vehicle, the vehicle AD mucosal vaccine from the antigen, and filed a patent application (Patent Document 1) are. Further the present inventors have found, and the amount of the antigen (V) vehicle AD (A) the amount of the weight ratio of V/A by adjusting the size, the specific production and selection of antibodies IgA IgA, both IgG antibody production and found that can be converted to, the mechanism of action of this mucosal vaccine and filed a patent (patent document 2). These patents Document 1, is 2, a fragment of a lung surfactant C B and the validity of the (peptide) is disclosed.
It should be noted that, as a synthetic peptide is associated with lung surfactant, which is to be made Patent Document 3-8.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • TOKUSHIMA UNIVERSITY
  • 発明者(英語)
  • KIDO, Hiroshi
  • TAKEI, Tsunetomo
  • MIZUNO, Dai
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
ご興味のある方は、下記「問合せ先」へ電子メールまたはFAXでご連絡ください。

PAGE TOP

close
close
close
close
close
close